


Opioid Use Disorder

Opioid use disorder is often associated with the commission of drug-related crimes (e.g., possession or distribution of drugs, forgery, burglary, robbery, larceny, receiving stolen goods; APA, 2013). Interpersonal difficulties, relationship difficulties, and unemployment are also often associated with opioid use disorder at all socioeconomic levels (APA, 2013). These factors are often important when assessing the appropriate level of care for treatment of the client. For example, a client who is engaging in intravenous heroin use, has had legal uses, and does not have a strong support system will likely need an intensive level of care (e.g., intensive outpatient, inpatient treatment).

Biological testing is also an important assessment component as it helps the counselor determine the appropriate level-of-care for client treatment. For example, clients who are using intravenous heroin may need a higher level of care (e.g., inpatient) and may require medical detoxification and/or medication-assisted treatments (e.g., buprenorphine, methadone) compared to those who are intermittently using intranasal heroin.





Methadone is used as a replacement therapy for clients with severe opioid use disorders. Methadone works by binding to the opioid receptor, thereby decreasing an individual's withdrawal symptoms associated with heroin and preventing cravings associated with use (O'Neill, 2014). Methadone typically suppresses opioid withdrawal and drug craving for 24 to 36 hours in most people with opioid use disorders (Center for Substance Abuse Treatment, 2005).

Buprenorphine works similar to methadone; however, it does not fully bind to the opioid receptor. Buprenorphine can be prescribed on an outpatient basis and does not require daily dosing. Naltrexone, an opiate antagonist, blocks and reverses the physical effects of opioids (i.e., one cannot get "high" on an opioid while on naltrexone; O'Neill, 2014). Naltrexone can be helpful in conjunction with outpatient counseling treatments.

Medication Assisted Treatment Resources:

Centers for Disease Control (CDC) overview of methadone maintenance treatment: http://www.cdc.gov/idu/facts/MethadoneFin.pdf

Information regarding accreditation of methadone maintenance programs: http://dpt.samhsa.gov/pdf/001218accred.pdf

SAMHSA Methadone and Pregnancy handout: http://store.samhsa.gov/shin/content//SMA14-4124/SMA14-4124.pdf

SAMHSA overview of buprenorphine treatment: http://buprenorphine.samhsa.gov/about.html

SAMHSA treatment with buprenorphine handout: http://store.samhsa.gov/shin/content//SMA14-4442/SMA14-4442.pdf

SAMHSA handout for opioid use treatment with naltrexone: https://store.samhsa.gov/shin/content/SMA12-4444/SMA12-4444.pdf

SAMHSA Hepatitis and Medication Assisted Treatment information: http://www.dpt.samhsa.gov/comor/hepatitis.aspx

SAMHSA handout for Hepatitis: http://store.samhsa.gov/product/Take-Action-Against-Hepatitis-C/SMA14-4853

Resource for overdose prevention:
Substance Abuse and Mental Health Services Administration's (SAMHSA) Opioid Overdose Toolkit: http://store.samhsa.gov/shin/content/SMA14-4742/Overdose_Toolkit.pdf

REFERENCES

American Psychiatric Association. (2013).
Washington, DC: Author.
Britt, E., Blampied, N. M., & Hudson, S. M. (2004). Motivational interviewing: A review. <i>A</i> 193–201.
Center for Substance Abuse Treatment. (2005). f
. Rockville, MD: Author. Available from: http://www.ncbi.nlm.nih.gov/books/NBK64158/
Chen, L. H., Hedegaard, H., & Warner, M. (2014).
1999, 2011. NCHS data brief, no 166. Hyattsville, MD:National Center for Health Statistics.
Dinwiddie, S. H., Shicker L., & Newman T. (2003). Prevalence of Hepatitis C among psychiatric patients in the public sector. A , f ,
Finney, J. W., Wilbourne, P. L., & Moos, R. H. (2007). Psychosocial treatments for substance use disorders. In P. E.
Nathan & J. M. Gorman (Eds.), A (pp. 179–202). New York, NY: Oxford.
Franken I. H., Hendriks ,V. M., & van den Brink, W. (2002). Initial validation of two opiate craving questionnaires
the obsessive compulsive drug use scale and the desires for drug questionnaire. $A = B = -27$, 27,
675–685
Hagan, H., Pouget, E. R., Des Jarais, D. C., &, Lelutiu-Weinberger, C. (2008). Meta-regression of hepatitis C virus
infection in relation to time since onset of illicit drug injection: The influence of time and place. American
Journal of Epidemiology, 168, 1099–1109.
Kelch, B. P., & Piazza, N. J. (2011). Medication-assisted treatment: Overcoming individual resistance among
members in groups whose membership consists of both users and nonusers of MAT: a clinical review.
$f \sim A \sim A \sim 6,307-318$
Loftis, J. M., Matthews, A. M., & Hauser, P. (2006). Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management. , 66, 155–174.
Mason B. J., Kocsis, J. H., Melia, D., Khuri, E. T., Sweeney, J., Wells, A., Kreek, M. J. (1998). Psychiatric
comorbidity in methadone maintained patients. fA , 17, 75–89.
Miller, W. R., & Rollnick, S. (2012).
New York, NY: Guilford.
Öhlund, L. S., & Grönbladh, L. (2009). Patterns of deviant career in the history of female methadone clients: An
exploratory study. $f = f$,
O'Neill, R. M. (2014). Substance abuse treatment planning. In V. Kress & M. Paylo (Eds.),
(pp. 225-257).
Columbus, Ohio: Pearson.
Wesson, D. R., & Ling, W. (2003). The Clinical Opiate Withdrawal Scale (COW

..., ..., ., 1